Newsroom

News & Press Releases


CeloNova BioSciences Inc. Named one of the Top 10 Cardiovascular Device Companies of 2019 by MedTech Outlook

San Antonio - April 5 2019

MedTech Outlook recognizes CeloNova BioSciences, Inc. as a pioneer at the forefront of cardiovascular innovation by naming the company as one of the top 10 cardiovascular companies of 2019.

CeloNova’s foundation of innovation has led to the successful manufacturing and marketing of a family of products, including the COBRA PzF NanoCoated Coronary Stent (NCS), based upon its proprietary Polyzene-F (PzF) nanocoating technology, a revolutionary surface coating designed to optimize implant interaction within the body.


Stent Thrombosis and Bleeding Highest within 30 Days of Procedure; Cobra PzF Stent Shows Promise as Means to Address

San Antonio - September 6 2018 - James Pitt (Dexur)

In Dexur’s national data, there were about 150,000 Percutaneous Cardiovascular Procedures With Coronary Artery Stent each year from 2013-2016 in Medicare-eligible inpatients. Stents are a diverse and fast-moving market. The most common devices are bare-metal or drug-eluting, but innovations like CeloNova’s polymer-coated Cobra PzF stent may have advantages for patients at high risk of bleeding. This advantage comes indirectly, through reducing the risk of stent thrombosis.


Clinical Data for Stenting High-Risk Patients Requiring Short DAPT

San Antonio - July/August 2018 (Cardiac Interventions Today)

Complications from bleeding after percutaneous coronary intervention (PCI) occur more frequently than myocardial infarctions and have a greater impact on mortality.1 Patients at high risk of bleeding and thrombosis have historically been a challenging population to treat due to concerns with the safety of drug-eluting stents (DES) with short dual antiplatelet therapy (DAPT) and the efficacy of bare-metal stents due to higher rates of restenosis.


Browse Our Archives